Body Composition and Bone Mineral Density After Ovarian Hormone Suppression with or Without Estradiol Treatment

Overview

Journal Menopause

Specialty Gynecology & Obstetrics

Date 2015 Mar 19

PMID 25783468

Citations 33

Authors

Karen L Shea

Kathleen M Gavin

Edward L Melanson

Ellie Gibbons

Anne Stavros

Pamela Wolfe

John M Kittelson

Sheryl F Vondracek

Robert S Schwartz

Margaret E Wierman

Wendy M Kohrt

Affiliations

Soon will be listed here.

Abstract

Objective: Suppression of ovarian hormones in premenopausal women on gonadotropin-releasing hormone agonist (GnRH(AG)) therapy can cause fat mass (FM) gain and fat-free mass (FFM) loss. Whether this is specifically caused by a decline in serum estradiol (E2) is unknown. This study aims to evaluate the effects of GnRH(AG) with placebo (PL) or E2 add-back therapy on FM, FFM, and bone mineral density (BMD). Our exploratory aim was to evaluate the effects of resistance exercise training on body composition during the drug intervention.

Methods: Seventy healthy premenopausal women underwent 5 months of GnRH(AG) therapy and were randomized to receive transdermal E2 (GnRH(AG) + E2, n = 35) or PL (GnRH(AG) + PL, n = 35) add-back therapy. As part of our exploratory aim to evaluate whether exercise can minimize the effects of hormone suppression, some women within each drug arm were randomized to undergo a resistance exercise program (GnRH(AG) + E2 + Ex, n = 12; GnRH(AG) + PL + Ex, n = 12).

Results: The groups did not differ in mean (SD) age (36 [8] and 35 [9] y) or mean (SD) body mass index (both 28 [6] kg/m). FFM declined in response to GnRH(AG) + PL (mean, -0.6 kg; 95% CI, -1.0 to -0.3) but not in response to GnRH(AG) + E2 (mean, 0.3 kg; 95% CI, -0.2 to 0.8) or GnRH(AG) + PL + Ex (mean, 0.1 kg; 95% CI, -0.6 to 0.7). Although FM did not change in either group, visceral fat area increased in response to GnRH(AG) + PL but not in response to GnRH(AG) + E2. GnRH(AG) + PL induced a decrease in BMD at the lumbar spine and proximal femur that was prevented by E2. Preliminary data suggest that exercise may have favorable effects on FM, FFM, and hip BMD.

Conclusions: Suppression of ovarian E2 results in loss of bone and FFM and expansion of abdominal adipose depots. Failure of hormone suppression to increase total FM conflicts with previous studies of the effects of GnRH(AG). Further research is necessary to understand the role of estrogen in energy balance regulation and fat distribution.

Citing Articles

Association between lifetime endogenous estrogen exposure and body composition metrics in postmenopausal women: findings from the Tehran Lipid and Glucose Study.

Rashidi E, Ramezani Tehrani F, Valizadeh M, Niroomand M, Mahdavi M, Farahmand M BMC Womens Health. 2024; 24(1):648.

PMID: 39707384 PMC: 11662808. DOI: 10.1186/s12905-024-03501-5.

Brown adipose tissue metabolism in women is dependent on ovarian status.

Blondin D, Haman F, Swibas T, Hogan-Lamarre S, Dumont L, Guertin J Am J Physiol Endocrinol Metab. 2024; 326(5):E588-E601.

PMID: 38477875 PMC: 11211003. DOI: 10.1152/ajpendo.00077.2024.

Low Levels of Serum Total Vitamin B12 Are Associated with Worse Metabolic Phenotype in a Large Population of Children, Adolescents and Young Adults, from Underweight to Severe Obesity.

Aureli A, Recupero R, Mariani M, Manco M, Carlomagno F, Bocchini S Int J Mol Sci. 2023; 24(23).

PMID: 38068910 PMC: 10706451. DOI: 10.3390/ijms242316588.

Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study.

Cheung Y, Hoermann R, Van K, Wu D, Healy J, Halim B Endocr Connect. 2023; 12(10).

PMID: 37522858 PMC: 10503251. DOI: 10.1530/EC-23-0076.

Detrimental Changes in Health during Menopause: The Role of Physical Activity.

Hulteen R, Marlatt K, Allerton T, Lovre D Int J Sports Med. 2023; 44(6):389-396.

PMID: 36807278 PMC: 10467628. DOI: 10.1055/a-2003-9406.

References

Surrey E . Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?. Curr Opin Obstet Gynecol. 2010; 22(4):283-8. DOI: 10.1097/GCO.0b013e32833b35a7. View

Tiidus P, Lowe D, Brown M . Estrogen replacement and skeletal muscle: mechanisms and population health. J Appl Physiol (1985). 2013; 115(5):569-78. PMC: 5504400. DOI: 10.1152/japplphysiol.00629.2013. View

Finkelstein J, Lee H, Burnett-Bowie S, Pallais J, Yu E, Borges L . Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013; 369(11):1011-22. PMC: 4142768. DOI: 10.1056/NEJMoa1206168. View

Kristensen K, Pedersen S, Vestergaard P, Mosekilde L, Richelsen B . Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. J Endocrinol. 1999; 163(1):55-62. DOI: 10.1677/joe.0.1630055. View

Franke H, van de Weijer P, Pennings T, van der Mooren M . Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril. 2000; 74(3):534-9. DOI: 10.1016/s0015-0282(00)00690-7. View

Heine P, Taylor J, Iwamoto G, Lubahn D, Cooke P . Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A. 2000; 97(23):12729-34. PMC: 18832. DOI: 10.1073/pnas.97.23.12729. View

Walker R, Lewis-Barned N, SUTHERLAND W, Goulding A, Edwards E, De Jong S . The effects of sequential combined oral 17beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. Menopause. 2001; 8(1):27-32. DOI: 10.1097/00042192-200101000-00006. View

Yamasaki H, Douchi T, Yamamoto S, Oki T, Kuwahata R, Nagata Y . Body fat distribution and body composition during GnRH agonist therapy. Obstet Gynecol. 2001; 97(3):338-42. DOI: 10.1016/s0029-7844(00)01181-9. View

Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani A . Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas. 2001; 39(2):125-32. DOI: 10.1016/s0378-5122(01)00194-3. View

10.

Gambacciani M, Ciaponi M, Cappagli B, Genazzani A . Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol. 2001; 185(5):1180-5. DOI: 10.1067/mob.2001.117669. View

11.

Nowicki M, Adamkiewicz G, Bryc W, Kokot F . The influence of luteinizing hormone-releasing hormone analog on serum leptin and body composition in women with solitary uterine myoma. Am J Obstet Gynecol. 2002; 186(3):340-4. DOI: 10.1067/mob.2002.120485. View

12.

Douchi T, Kuwahata R, Yamasaki H, Yamamoto S, Oki T, Nakae M . Inverse relationship between the changes in trunk lean and fat mass during gonadotropin-releasing hormone agonist therapy. Maturitas. 2002; 42(1):31-5. DOI: 10.1016/s0378-5122(02)00004-x. View

13.

Wu F, Ames R, Clearwater J, Evans M, Gamble G, Reid I . Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol (Oxf). 2002; 56(6):703-11. DOI: 10.1046/j.1365-2265.2002.01534.x. View

14.

Palomba S, Morelli M, Carlo C, Noia R, Pellicano M, Zullo F . Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone. Fertil Steril. 2002; 78(1):63-8. DOI: 10.1016/s0015-0282(02)03149-7. View

15.

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

16.

Mattiasson I, Rendell M, Tornquist C, Jeppsson S, Hulthen U . Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. Horm Metab Res. 2002; 34(10):583-8. DOI: 10.1055/s-2002-35420. View

17.

Kanaya A, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V . Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003; 138(1):1-9. DOI: 10.7326/0003-4819-138-1-200301070-00005. View

18.

Hassager C, Christiansen C . Estrogen/gestagen therapy changes soft tissue body composition in postmenopausal women. Metabolism. 1989; 38(7):662-5. DOI: 10.1016/0026-0495(89)90104-2. View

19.

Roux C, Pelissier C, Listrat V, Kolta S, SIMONETTA C, Guignard M . Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporos Int. 1995; 5(3):185-90. DOI: 10.1007/BF02106098. View

20.

Paoletti A, Serra G, Cagnacci A, Vacca A, Guerriero S, SOLLA E . Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril. 1996; 65(4):707-10. View